Business Context and Reporting Period
This Form 6-K filing by Anchiano Therapeutics Ltd. (referred to as Chemomab Therapeutics Ltd. in metadata) covers the month of June 2019, specifically dated June 18, 2019. The registrant is a foreign private issuer headquartered in Jerusalem, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
- Delisting: On June 18, 2019, the Company completed the voluntary delisting of its ordinary shares from the Tel Aviv Stock Exchange.
- Trading Status: The Company's American Depositary Shares (ADS), each representing five ordinary shares, continue to trade on the Nasdaq Capital Market under the symbol "ANCN."
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the operational change of delisting from the Tel Aviv exchange. The document incorporates a press release as Exhibit 99.1.
Investor Verification Checklist
- Verify the continued trading status and liquidity of ADS on the Nasdaq Capital Market under symbol "ANCN."
- Confirm the finalization of the delisting process from the Tel Aviv Stock Exchange.
- Review the attached press release (Exhibit 99.1) for any additional details regarding the rationale for delisting.